Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study

This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with HCV GT1.

Start Date01 Mar 2017

Sponsor / Collaborator

AbbVie, Inc.

JPRN-UMIN000026640

/ CompletedNot ApplicableIIT

Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients - Virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients

Start Date16 Jan 2017

Sponsor / Collaborator-

NCT02807402

/ CompletedNot Applicable

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania

This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin (RBV) in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Romania.

Start Date14 Jul 2016

Sponsor / Collaborator

AbbVie, Inc.

[+1]

100 Clinical Results associated with Paritaprevir

100 Translational Medicine associated with Paritaprevir

100 Patents (Medical) associated with Paritaprevir

635

Literatures (Medical) associated with Paritaprevir

01 Nov 2024·Drug Resistance Updates

crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer

Article

Author: Xie, Xiaoming ; Zou, Yutian ; Dai, Danian ; Deng, Xinpei ; Yang, Anli ; Xie, Jindong ; Tang, Hailin ; Zhou, Zhigang ; Wang, Jin ; Zhang, Jinhui ; Chen, Bo ; Wu, Tao

AIMSWith the wide application of trastuzumab deruxtecan (T-DXd), the survival of HER2-low breast cancer patients is dramatically improved. However, resistance to T-DXd still exists in a subset of patients, and the molecular mechanism remains unclear.METHODSAn in vivo shRNA lentiviral library functional screening was performed to identify potential circular RNA (crRNA) that mediates T-DXd resistance. RNA pull-down, mass spectrometry, RNA immunoprecipitation, and co-immunoprecipitation assays were conducted to investigate the molecular mechanism. Ferroptosis was detected using C11-BODIPY, Liperfluo, FerroOrange staining, glutathione quantification, malondialdehyde quantification, and transmission electron microscopy. Molecular docking, virtual screening, and patient-derived xenograft (PDX) models were used to validate therapeutic agents.RESULTSVDAC3-derived crRNA (crVDAC3) ranked first in functional shRNA library screening. Knockdown of crVDAC3 increased the sensitivity of HER2-low breast cancer cells to T-DXd treatment. Further mechanistic research revealed that crVDAC3 specifically binds to HSPB1 protein and inhibits its ubiquitination degradation, leading to intracellular accumulation and increased levels of HSPB1 protein. Notably, suppression of crVDAC3 dramatically increases excessive ROS levels and labile iron pool accumulation. Inhibition of crVDAC3 induces ferroptosis in breast cancer cells by reducing HSPB1 expression, thereby mediating T-DXd resistance. Through virtual screening and experimental validation, we identified that paritaprevir could effectively bind to crVDAC3 and prevent its interaction with HSPB1 protein, thereby increasing ubiquitination degradation of HSPB1 protein to overcome T-DXd resistance. Finally, we validated the enhanced therapeutic efficacy of T-DXd by paritaprevir in a HER2-low PDX model.CONCLUSIONThis finding reveals the molecular mechanisms underlying T-DXd resistance in HER2-low breast cancer. Our study provides a new strategy to overcome T-DXd resistance by inhibiting the interaction between crVDAC3 and HSPB1 protein.

01 Jul 2024·Journal of Pharmacy and Bioallied Sciences

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease

Article

Author: Aljarallah, Badr M.

ABSTRACTThis study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV/PTV/r±DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.

01 Jun 2024·Drug Metabolism and Disposition

HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation

Article

Author: Hackett, John C ; Work, Hannah M ; Lampe, Jed N

The hepatitis C virus (HCV) poses a great risk to pregnant people and their developing fetus, yet no HCV antiviral treatment guidelines have been established. While there has been a substantial increase in the development of HCV antivirals, the effect they have on the developing fetus remains poorly defined. Many of these drugs are metabolized through the cytochrome P450 CYP3A pathway, which is mediated by cytochrome P450 3A7 (CYP3A7) in the fetus and developing infant. In this study, we sought to investigate the effect HCV antivirals have on CYP3A7 metabolism, as this CYP enzyme plays a vital role in proper fetal and neonatal development. Of the 13 HCV antivirals we investigated, 8 (∼62%) inhibited CYP3A7 metabolic activity by 50% or more at a concentration of 20 µM. Furthermore, paritaprevir, asunaprevir, simeprevir, danoprevir, and glecaprevir all had observed half-maximal inhibitory concentrations between the range of 10 and 20 µM, which is physiologically relevant in comparison with the K_m of dehydroepiandrosterone-sulfate (DHEA-S) oxidation (reported to be between 5 and 20 µM). We also discovered that paritaprevir is a time-dependent inhibitor of CYP3A7, which shifts the IC₅₀ ∼twofold from 11 µM to 5 µM. Upon further characterization, paritaprevir inactivates DHEA-S metabolism by CYP3A7, with K_I and K_inact values of 4.66 µM and 0.00954 minute^-1, respectively. Depending on treatment plan and off-label drug use, HCV treatment could adversely affect the fetal-maternal communication axis by blocking fetal CYP3A7 metabolism of important endogenous hormones. SIGNIFICANCE STATEMENT: The prevalence of HCV in pregnant people is estimated at between 1% and 8% of the global population, yet little to no information exists about the risk antiviral treatment poses to the developing fetus. There is a potential risk of drugs adversely affecting mother-fetal communication by inhibiting fetal hepatic CYP3A7, an integral enzyme for estriol production. We discovered that five HCV antivirals inhibited DHEA-S metabolism by CYP3A7, and paritaprevir inactivated the enzyme. Our studies demonstrate the potential threat these drugs pose to proper fetal development.

News (Medical) associated with Paritaprevir

30 Apr 2021

·www.biospace.com

Research Roundup: Underlying Conditions, COVID-19 Severity and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. More Data on Underlying Conditions and COVID-19 Severity A study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland has further defined the association between comorbidities and poor outcomes with COVID-19. The study took place between March and July 2020 and collected national data in Ireland from both hospital and community settings. It collected data for almost 20,000 confirmed cases of COVID-19. The results were published in The Lancet Regional Health – Europe. Of the patients studied, there were 1,476 deaths, 2,811 hospitalizations, and 438 ICU admissions. The conditions that carried the most risk were chronic heart disease, a chronic neurological condition, chronic kidney disease and cancer. Morbid obesity was also identified as being associated with severe outcomes. “Previous studies conducted have suggested that specific underlying conditions influence adverse health outcomes among those with a confirmed diagnosis of COVID-19,” said Kathleen Bennett, associate professor in Biostatistics, RCSI. “However, the majority of these studies have focused on hospital-based or local populations only. This study is the first population-based research to capture data across all settings in Ireland, including both community and hospital settings and so it gives us a better picture of the impact of the disease on patients at the population level.” Gilead’s Remdesivir Plus Hep C Drugs Effective Against COVID-19 Researchers with Mount Sinai Hospital and Mount Sinai School of Medicine tested a combination of Gilead’s remdesivir, an antiviral drug, with repurposed drugs for hepatitis C virus (HCV). The combinations, they found, were 10-times more effective at inhibiting SARS-CoV-2, the virus behind COVID-19. Four HCV drugs in combination with remdesivir improved the efficacy of remdesivir. They were simeprevir, vaniprevir, paritaprevir, and grazoprevir. The research group tested 10 HCV drugs, some already approved by the U.S. Food and Drug Administration (FDA). They utilized a supercomputer to model how drugs bind to viral proteins and predicted that those 10 would bind tightly to the SARS-CoV-2 Main protease (Mpro). They also found that seven of the drugs inhibited the SARS-CoV-2 protease. They then tested the seven drugs in monkey and human cells in culture. Four of the HCV drugs inhibited a different SARS-CoV-2 protease called PLpro. It was the four drugs that targeted PLpro that increased the efficacy of remdesivir by as much as 10-fold. While remdesivir must be dosed intravenously, the four HCV drugs are oral. Type 2 Diabetes Associated with Muscle Gene Researchers at Lund University found that in type 2 diabetes, a specific gene related to muscle cells is less active than it is in other people. The gene, VPS39, is important for when muscle cells absorb sugar from blood and build new muscle. In type 2 diabetes, the body’s ability to generate insulin is impaired, resulting in chronically increased blood sugar. The muscles are generally worse at absorbing sugar from food, and this muscle function and strength are typically impaired in type 2 diabetic patients. Their study, which was on muscle stem cells in type 2 diabetes patients compared to healthy controls, found that there were more than twice as many epigenetic changes in the type 2 diabetes group during the differentiation from muscle stem cell to mature muscle cells. Muscle-specific genes were not regulated normally, and epigenetics did not appear to function in the same way in cells from people with type 2 diabetes did. How Brain Cells in Alzheimer’s Patients Lose Their Identity Investigators with the Salk Institute grew neurons that resemble better than ever before the brain cells in older patients. It appears to have given them insight into how the brain cells go off-track in Alzheimer’s patients, losing their cellular identity. The brain cells were characterized by markers of stress in addition to changes where the cells become less specialized. This is similar to what has been observed in cancer cells. The researchers collected skin cells from 13 sporadic, age-related Alzheimer’s patients, as well as cells from three people with the rarer, inherited form of Alzheimer’s. Their controls were skin cells from 19 people age-matched but without Alzheimer’s. Using fibroblasts, they induced neurons, then compared the molecular differences in the cells. They found that the cells from people with Alzheimer’s had specific characteristics different from the healthy control cells. The Alzheimer’s cells lacked synaptic structures, which are vital to sending signals to each other. There were also changes in signaling pathways, which control cell function, an indication the cells were under stress. They also found that the induced Alzheimer’s neurons had similar molecular signatures to immature nerve cells found in the developing brain. What this was interpreted to mean was the Alzheimer’s-based cells had lost their mature identity. A New Anti-Aging Compound Scientists at Washington University School of Medicine found a natural compound, nicotinamide mononucleotide (NMN), that in earlier studies seemed to counteract aging and improved metabolic health in mice, also had positive clinical effects in people. They conducted a clinical trial of postmenopausal women with prediabetes. They demonstrated that NMN improved the ability of insulin to increase glucose uptake in skeletal muscle. This ability is often abnormal in obese, prediabetic or type 2 diabetics. NMN improved expression of genes involved in muscle structure are remodeling. However, it did not lower blood sugar levels, blood pressure, improve blood lipids, increase insulin sensitivity in the liver, reduce fat in the liver or decrease circulating markers of inflammation as was observed in mice. “Although our study shows a beneficial effect of NMN in skeletal muscle, it is premature to make any clinical recommendations based on the results from our study,” said Samuel Klein, senior investigator and the William H. Danforth Professor of Medicine and Nutritional Science and director of the Center for Human Nutrition. “Normally, when a treatment improves insulin sensitivity in skeletal muscle, as is observed with weight loss or some diabetes medications, there also are related improvement in other markers of metabolic health, which we did not detect in our study participants.”

04 Apr 2012

·www.biospace.com

Enanta Pharmaceuticals, Inc. Announces Positive Phase 2 Results From Interferon-Free Combination Studies With ABT-450 for Hepatitis C Treatment to be Presented at EASL

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott. ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at . Phase 2 Data Highlights In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients. In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r. In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment. In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24). "The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new interferon-free, all-oral regimens for previously treated and treatment-naive patients with HCV," said Jay Luly, Ph.D., President and CEO of Enanta. "Enanta's involvement in five distinct HCV drug classes provides multiple avenues to pursue our goal of bringing to patients innovative therapies that are safer and more effective than current treatments." Oral Presentations Oral Presentation, Eric Lawitz et al.; Thursday, April 19, 16:00-18:00 CET / 10:00 am - 12:00 pm EDT. A 12-week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naive HCV IL28B-CC Genotype-1-Infected Subjects The objectives of the 12-week, phase 2 study were to assess the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450/r 150/100 mg QD and ABT-072 400 mg QD + ribavirin administered for 12 weeks. The study was conducted in 11 treatment naive adults from multiple ethnic backgrounds with non-cirrhotic HCV GT1 (8 GT 1a, 3 GT 1b). Ribavirin 1000-1200 mg/day was weight-based and dosed twice daily. The primary endpoint was percentage of patients with HCV RNA <25 IU/ml from week 4 through 12. Other trial endpoints include early virologic response, RVR and SVR through 24 weeks. 100 percent of patients maintained HCV RNA levels <25 IU/mL from weeks 4 through 12 of treatment, and all had undetectable HCV RNA from week 5 to the end of treatment. 91 percent of patients achieved SVR24, In the trial, the most common adverse events reported were headache, fatigue, nausea and dry skin. There were no premature discontinuations. Late-Breaking Oral Presentation, Fred Poordad, et al.; Saturday, April 21, 15:30-17:30 CET / 9:30-11:30 am EDT. 12-Week Interferon-Free Regimen of ABT-450/r+ABT-333+Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naive HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders The objectives of this phase 2 study were to assess safety and tolerability 12-week interferon-free regimens in HCV GT1 patients who were either treatment naive or previous non-responders. The trial had three arms with three primary end points rapid virological response (RVR) at week 4 and SVR at weeks 4 and 12. Enrollment was open to GT1-infected patients regardless of IL28B host genotype and ribavirin dosing was weight-based. 95 percent (18 of 19) of treatment-naive patients infected with HCV GT1 (17 GT 1a, 2 GT 1b) achieved SVR12 with ABT 450/r 250/100 mg dosed once daily (QD) +ABT-333 400 mg dosed twice daily (BID) + ribavirin (Arm 1). 93 percent (13 of 14) of treatment- naive patients infected with HCV GT1 (11 GT 1a, 3 GT1b) achieved SVR12 with ABT 450/r 150/100 mg QD +ABT-333 400 mg BID + ribavirin (Arm 2). 47 percent (8 of 17) of patients with HCV GT1 (16 GT1a, 1 GT1b) who had previously not responded to other HCV treatments achieved SVR12 with ABT 450/r 150/100 mg QD +ABT-333 400 mg BID + ribavirin (Arm 3). One patient in Arm 1 discontinued due to asymptomatic isolated ALT/AST elevations at week 2. One patient in Arm 2 discontinued due to noncompliance in week 1. All remaining patients in Arms 1 and 2 completed treatment and achieved SVR12. In Arm 3, six patients experienced viral breakthrough while on treatment and three patients relapsed after treatment stopped. In the trial the most common adverse events were fatigue (42 percent), nausea (22 percent) and headache (20 percent). Abbott is developing ABT-450 with low dose ritonavir (ABT-450/r) which enhances the pharmacokinetic properties of ABT-450, allowing for once daily dosing. The use of ritonavir 100 mg with ABT-450 for the treatment of HCV is investigational. Poster Presentations Poster #867, Tami Pilot-Matias et al.; Friday, April 20 (11:00-11:30, 12:30-14:00, 15:30-16:00 CET) "In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450, NS5A inhibitor ABT-267, and non-nucleoside NS5B polymerase inhibitor ABT-333" Poster #1187, Eric Lawitz et al; Saturday, April 21 (11:00-11:30, 12:30-13:30, 15:00-15:30 CET) "ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results" Poster #1200, Christopher M. Owens et al.; Saturday, April 21 (11:00 11:30, 12:30 13:30, 15:00 15:30 CET) "Antiviral Activity of EP-NI266, a Potent Nucleotide HCV Polymerase Inhibitor" About the Hepatitis C Virus Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated. About Enanta Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors and combinations of inhibitors targeted against the Hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes protease (partnered with Abbott), NS5A (partnered with Novartis), nucleotide polymerase, and a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Through its partnership with Abbott, collaboration protease inhibitor ABT-450 is being evaluated in combination with Abbott's non-nucleoside polymerase and NS5A inhibitors. Additionally, the Company has created a new class of antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at . For Enanta Investor Relations, please contact: Paul Mellett 617-607-0761 For Enanta Public Relations,please contact MacDougall Biomedical Communications: Kari Watson 781-235-3060 or kwatson@macbiocom.com SOURCE Enanta Pharmaceuticals, Inc.

CollaborateBest in ClassSmall molecular drug

100 Deals associated with Paritaprevir

External Link

KEGG	Wiki	ATC	Drug Bank
D10580	Paritaprevir	-	DB09297

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic hepatitis C genotype 3	Phase 3	-	AbbVie, Inc.	01 Sep 2011
Chronic hepatitis C genotype 1	Phase 3	US	AbbVie, Inc.	01 Mar 2010
Chronic hepatitis C genotype 1	Phase 3	PR	AbbVie, Inc.	01 Mar 2010
Hepatitis C	Phase 3	-	Abbott Laboratories	-
Hepatitis C	Phase 3	-	Abbott Laboratories	-
Hepatitis C	Phase 3	-	Enanta Pharmaceuticals, Inc.	-
Hepatitis C	Phase 3	-	Enanta Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01609933 (CTgov)	Phase 2	Hepatitis C, Chronic	32	paritaprevir+pegylated interferon alpha-2a (pegIFN)+ritonavir+ribavirin (RBV)+ABT-267	fjlmugscyn(vevdlvtgmo) = yoitogdhji arbheotaci (mpbohsbijj, kijajsiicu - xurwppgiug) View more	-	19 Jun 2018
NCT01458535 (Navigator, CTgov)	Phase 2	Chronic hepatitis C genotype 3	61	ABT-450+ritonavir+Ribavirin+ABT-267 (ABT-450/r and ABT-267 Plus RBV in Genotype 1 Participants)	dyvzfxltjk(cxandchvkr) = pipwdemgix iifnlyzsqr (drafgaobpe, ejslpqlcwq - lwzpaozhpm) View more	-	11 Jul 2016
				ABT-450+ritonavir+Ribavirin+ABT-267 (ABT-450/r and ABT-267 Plus RBV in Genotype 2 Participants)	dyvzfxltjk(cxandchvkr) = ymquxsdodp iifnlyzsqr (drafgaobpe, qwmkgeqlyn - praotrfajs) View more
TURQUOISE-I Part 2 (IAS2016)	Not Applicable	HIV Infections \| Hepatitis C	227	Ombitasvir + Paritaprevir/r + Dasabuvir + Ribavirin	(tlthjbrolb) = ofesfubvmj apabgybpau (bgureqaxdg )	-	01 Jan 2016
				Ombitasvir + Paritaprevir/r + Dasabuvir	(tlthjbrolb) = cmuokjeaxx apabgybpau (bgureqaxdg )
NCT01685203 (PEARL-I, CTgov)	Phase 2	Hepatitis C, Chronic	316	ABT-450+ ritonavir+ABT-267 (Group 1)	iedokkjwcl(gypyinsimv) = iwkzmpgxzl qzggzrddsd (tzugqyqdso, dogpeeowuo - ighprsbber) View more	-	04 Aug 2015
				ABT-450+ ritonavir+ABT-267 (Group 2)	iedokkjwcl(gypyinsimv) = yzwqxopdgm qzggzrddsd (tzugqyqdso, rgragkpeck - cvlxylgeja) View more
NCT01563536 (CTgov)	Phase 2	Hepatitis C	12	ABT-450+ABT-333+ribavirin+Ritonavir+ABT-267 (ABT-267 1.5 mg, Then ABT-267, ABT-450/r, ABT-333, Plus RBV)	nwicrsdnqz(yqjplzevkt) = zdkxxohnmf xevcfxtepd (hwbhnbwypg, vygveljugs - jisbhpzkwf) View more	-	08 Jan 2015
				ABT-450+ABT-333+ribavirin+Ritonavir+ABT-267 (ABT-267 25 mg, Then ABT-267, ABT-450/r, ABT-333, Plus RBV)	nwicrsdnqz(yqjplzevkt) = umovweycgt xevcfxtepd (hwbhnbwypg, qhuervmein - wdwtdmyffi) View more
NCT01221298 (CTgov)	Phase 2	Chronic hepatitis C genotype 1	11	ABT-450+ABT-072+Ritonavir+Ribavirin	lrhbsupcym(awkthacbbe) = brskrewmxv irlsfkfenm (vfpyeoqkep, unptlrlsdv - fkafwsvwax) View more	-	08 Jan 2015
NCT01306617 (CTgov)	Phase 2	Chronic hepatitis C genotype 1	50	ABT-450+ABT-333+ribavirin+ritonavir (ABT-450/r (250/100 mg) and ABT-333 Plus RBV in Treatment-naïve)	mlncvevyim(hyrrlpxpfo) = kmyntcpdqz kpsvuzinxu (slcmhdsydm, dcmvikrzqs - jbazmzjygy) View more	-	08 Jan 2015
				ABT-450+ABT-333+ribavirin+ritonavir (ABT-450/r (150/100 mg) and ABT-333 Plus RBV in Treatment-naïve)	mlncvevyim(hyrrlpxpfo) = hinzbuiqgv kpsvuzinxu (slcmhdsydm, rnngteeciy - obryhmmbuj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Paritaprevir

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation